Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CTXR Stock Forecast 2025-2026
$0.91
Current Price
$9.61M
Market Cap
Buy 1
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to CTXR Price Targets
+557.2%
To High Target of $6.00
+557.2%
To Median Target of $6.00
+557.2%
To Low Target of $6.00
CTXR Price Momentum
-1.1%
1 Week Change
+18.2%
1 Month Change
-94.0%
1 Year Change
-77.3%
Year-to-Date Change
-96.5%
From 52W High of $26.25
+40.5%
From 52W Low of $0.65
📊 TOP ANALYST CALLS
Did CTXR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Citius is one of their latest high-conviction picks.
Latest CTXR Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, CTXR has a neutral consensus with a median price target of $6.00 (ranging from $6.00 to $6.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $0.91, the median forecast implies a 557.2% upside. This outlook is supported by 1 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jason Kolbert at D. Boral Capital, projecting a 557.2% upside. Conversely, the most conservative target is provided by Jason Kolbert at D. Boral Capital, suggesting a 557.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CTXR Analyst Ratings
1
Buy
1
Hold
0
Sell
CTXR Price Target Range
Low
$6.00
Average
$6.00
High
$6.00
Current: $0.91
Latest CTXR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CTXR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 10, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $6.00 |
| Jun 9, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $9.00 |
| May 23, 2025 | Maxim Group | Jason McCarthy | Hold | Downgrade | $0.00 |
| May 15, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $9.00 |
| Feb 18, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $9.00 |
| Jan 7, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $9.00 |
| Dec 30, 2024 | D. Boral Capital | Jason Kolbert | Buy | Upgrade | $9.00 |
| Nov 22, 2024 | D. Boral Capital | Jason Kolbert | Hold | Downgrade | $0.00 |
| Nov 12, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $4.00 |
| Nov 11, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $6.00 |
| Aug 19, 2024 | EF Hutton | Jason Kolbert | Buy | Maintains | $6.00 |
| Aug 8, 2024 | EF Hutton | Jason Kolbert | Buy | Maintains | $6.00 |
| Aug 5, 2024 | EF Hutton | Jason Kolbert | Buy | Maintains | $6.00 |
| Jul 15, 2024 | EF Hutton | Jason Kolbert | Buy | Initiates | $6.00 |
| May 31, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $4.00 |
| Feb 14, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $4.00 |
| Aug 10, 2023 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $4.00 |
| Aug 1, 2023 | HC Wainwright & Co. | Buy | Maintains | $0.00 | |
| May 30, 2023 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $6.00 |
| Apr 3, 2023 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $6.00 |
Citius Pharmaceuticals Inc. (CTXR) Competitors
The following stocks are similar to Citius based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Citius Pharmaceuticals Inc. (CTXR) Financial Data
Citius Pharmaceuticals Inc. has a market capitalization of $9.61M with a P/E ratio of -0.2x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -60.5%.
Valuation Metrics
Market Cap
$9.61M
Enterprise Value
$12.60M
P/E Ratio
-0.2x
PEG Ratio
4.7x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+0.3%
Current Ratio
0.4x
Debt/Equity
1.5x
ROE
-60.5%
ROA
-25.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Citius Pharmaceuticals Inc. (CTXR) Business Model
About Citius Pharmaceuticals Inc.
What They Do
Develops critical care biopharmaceutical products.
Business Model
Citius Pharmaceuticals operates as a clinical-stage biopharmaceutical company, focusing on developing innovative therapeutic solutions for unmet medical needs in critical care. The company generates revenue through the commercialization of its products, particularly in oncology and anti-infectives, leveraging proprietary technologies and strategic partnerships to enhance treatment efficacy.
Additional Information
Citius has a diverse product pipeline addressing issues such as catheter-related bloodstream infections and offers unique formulations for conditions like hemorrhoids and acute respiratory distress syndrome. The company's headquarters is located in Cranford, New Jersey, positioning it strategically within the pharmaceutical industry to improve patient outcomes in hospital-based settings.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
22
CEO
Mr. Leonard L. Mazur
Country
United States
IPO Year
2017
Website
citiuspharma.comCitius Pharmaceuticals Inc. (CTXR) Latest News & Analysis
Latest News
Quick Summary
Citius Oncology is preparing for the commercial launch of LYMPHIR™, an FDA-approved immunotherapy for relapsed or refractory cutaneous T-cell lymphoma, nearing completion of preparations.
Why It Matters
The nearing commercial launch of LYMPHIR™ positions Citius Oncology to tap into a new revenue stream, potentially boosting stock performance and investor confidence in CTOR and CTXR.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Citius Pharmaceuticals closed a registered direct offering, raising $6 million upfront, with potential gross proceeds of up to $9.8 million from short-term warrants. The offering includes 4.92 million shares at $1.22 each.
Why It Matters
Citius Pharmaceuticals raising $6 million upfront and potential $9.8 million through warrants indicates liquidity and growth potential, impacting stock valuation and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Citius Pharmaceuticals Inc. announced a registered direct offering of 4.92 million shares at $1.22 each, with potential gross proceeds of $9.8 million from short-term warrants.
Why It Matters
Citius Pharmaceuticals' capital raise of $6 million plus potential additional funds indicates financial backing for growth, impacting share value and investor confidence in its future prospects.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Citius Pharmaceuticals (Nasdaq: CTXR) reported its business and financial results for Q1 FY2025, ending March 31, focusing on first-in-class critical care products.
Why It Matters
Citius Pharmaceuticals' quarterly results can influence stock performance, impact investor sentiment, and signal the company's growth potential and financial health in the biopharmaceutical sector.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Citius Pharmaceuticals CEO Leonard Mazur will present at the Jefferies Global Healthcare Conference on June 5, 2025, at 3:10 pm ET in New York City.
Why It Matters
CEO presentations at major conferences can signal upcoming developments or strategic insights, influencing investor sentiment and stock performance for Citius Pharmaceuticals and its subsidiary.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Citius Pharmaceuticals Inc. has agreed to sell 1,739,131 shares of common stock at $1.15 each, as part of a financing strategy to support its critical care product development.
Why It Matters
Citius Pharmaceuticals' share issuance at $1.15 indicates capital raising efforts, impacting liquidity and stock valuation, which can influence investor sentiment and market performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CTXR Stock
What is Citius Pharmaceuticals Inc.'s (CTXR) stock forecast for 2025?
Based on our analysis of 4 Wall Street analysts, Citius Pharmaceuticals Inc. (CTXR) has a median price target of $6.00. The highest price target is $6.00 and the lowest is $6.00.
Is CTXR stock a good investment in 2025?
According to current analyst ratings, CTXR has 1 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.91. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CTXR stock?
Wall Street analysts predict CTXR stock could reach $6.00 in the next 12 months. This represents a 557.2% increase from the current price of $0.91. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Citius Pharmaceuticals Inc.'s business model?
Citius Pharmaceuticals operates as a clinical-stage biopharmaceutical company, focusing on developing innovative therapeutic solutions for unmet medical needs in critical care. The company generates revenue through the commercialization of its products, particularly in oncology and anti-infectives, leveraging proprietary technologies and strategic partnerships to enhance treatment efficacy.
What is the highest forecasted price for CTXR Citius Pharmaceuticals Inc.?
The highest price target for CTXR is $6.00 from Jason Kolbert at D. Boral Capital, which represents a 557.2% increase from the current price of $0.91.
What is the lowest forecasted price for CTXR Citius Pharmaceuticals Inc.?
The lowest price target for CTXR is $6.00 from Jason Kolbert at D. Boral Capital, which represents a 557.2% increase from the current price of $0.91.
What is the overall CTXR consensus from analysts for Citius Pharmaceuticals Inc.?
The overall analyst consensus for CTXR is neutral. Out of 4 Wall Street analysts, 1 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $6.00.
How accurate are CTXR stock price projections?
Stock price projections, including those for Citius Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 7:09 PM UTC